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Abstract  
Hematopoietic stem and progenitor cells (HSPCs) are non-stop travelers throughout body in both time and 
space. Understanding the mechanism of HSPCs homing and mobilization is important to enhance the efficacy at 
bone marrow transplantation and cellular therapy. Mobilized HSPCs has largely replaced than the use of bone 
marrow as a source of stem cells for both allogeneic and autologous stem cell transplantation. This review 
describes the specific factors which play a key role in homing and mobilization of HSPCs, includes SDF-1 and its 
receptor CXCR4, proteases (MMPs and CPM). Moreover, chemokines inducing rapid HPSCs mobilization would 
be discussed. In this article we showed that many factors such as adhesion molecules and SDF-1/CXCR4 have 
critical roles in homing hematopoietic stem cells and G.CSF, MMPs, adhesion molecules and ROS involvement in 
mobilization of stem cells. According to above, we can be rich the peripheral blood of HSPCS using of this factors 
and antagonist for this receptors on the osteoblastic cells or/and HSPCs to bone marrow transplant. 
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Introduction 
Hematopoietic stem cells (HSPCs) are distinct 
cells have been identified by their CD34+  markers 
on their surface and are predominantly located in the 
BM microenvironment, which is referred to as their 
niches (1).The existence of a niche in which HSPCs 
reside within the BM cavity was proposed more than 
30 years ago (2). The BM niche is identified as a 
local microenvironment , containing different 
population of cells such as stromal cells, osteoblasts, 
endothelial cells, adipocytes and fibroblasts (3). 
There are two kinds of niches for long maintaining of 
HSPCSs in the BM including the endosteal surface 
(known as the osteoblast niche) and sinusoidal 
endothelium (the vascular niche). Mounting evidences 
revealed later that the BM niche provides not only a 
static structural support but topographical information 
and the appropriate physiological cues to control the 
dynamic balance of  HSPCs quiescence, self-renewal, 
differentiation and apoptosis, as well as HSPC 
localization and migration (4) (5). It is now apparent 
that rather than randomly distributed in the BM, 
HSPCs , are localized along the endosteal surface of 
bone in close proximity to the osteoprogenitors and 
osteoblasts and around blood vessels (6). Different 
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HSPCs subsets are distributed to distinct locations 
according to their stages of differentiations with the 
most dormant and primitive HSPCs residing in niche 
characterized by poor blood perfusion (7). Whereas 
the endosteal zone is thought to favor the 
maintenance of cells in an undifferentiated state, the 
centrally located vascular niche in the BM allows for 
differentiation .Mobilization is accompanied by a 
suppression of endosteal osteoblasts, leading to a 
decreased expression of factors required for retention 
and self-renewal of HSPCs (8). Furthermore, 
depletion of endosteal macrophages (osteomacs) 
form a canopy over mature osteoblasts at sites of 
bone formation and support osteoblast function to 
elicit robust mobilization of HSPCs. These data 
suggest critical role of BM macrophages in the 
maintenance of endosteal HSPC niches (8). Such 
nestin+ MSCs express genes involving in HSPCs 
maintenance and their abrogation would significantly 
reduce  in the number of BM-HSPCs, and their 
mobilization towards extramedullary sites (8). 
HSPCs are also retained in niche by adhesion 
molecules directed at both the levels of cell-to-cell 
interaction and attachment to ECM components.  
2. Homing 
2-1.HSPCs homing to Bone marrow niche. 
HSPC homing is a multistep process in which 
circulating HSPCs are exposed to signals from 
chemokines secreted to the local milieu that lead to 
the activation of surface integrins and firm arresting 
of HSPC on the endothelium. In the following for 
transendothelia migration directed by chemokine 
gradient for HSPC homing process, the tissues 
should be destroyed; for example BM, spleen, bone 
marrow barrier and even blood; so several cytokines 
and chemokines are released to repair the destroyed 
tissues, so both repairing and homing are significant. 
There have been numerous reviews about HSPCs 
homing (9-18).Homing is identified as the early 
event that lodges and firmly retains HSPCs in the 
BM prior to their proliferation and expansion (16). 
Homing occurs when HSPCs are intravenously 
administered to  interact with the micro vascular 
endothelial cells of the BM, adhere to the vessel wall 
with sufficient strength to overcome the considerable 
shear stress exerted by the flowing blood. Finally, 
HSPCs extravagate across the vascular wall along an 
SDF-1 gradient generated by osteoblasts in the 
endostel niche (13, 14). Early on, the homing process 
was graphically described as the “rolling, crawling and 
resting” of HSPCs into the marrow stromal space (19). 
Several studies have already identified the significant 
contributions of a wide variety of adhesion molecules 
and their receptors in the mediating cell-to-cell and 
cell-to-matrix interaction (20, 21). Furthermore, the 
roles of the SDF-1/CXCR4 axis in the retention of 
HSPCs in the BM niches were established (22-24). 
Proteolytic enzymes with  degrading ECM 
components play a critical role in HSPCs homing (25). 
Further, cytokines such as GM-CSF, IL-3 and SCF by 
activating VLA-4 and VLA-5 increase the 
adhesiveness of HSPCs, as well as Flt3-ligand, 
SCF,IL-3,IL-6 and HGF with  up regulation  the 
expression of CXCR4 on HSPCs are factors in the 
homing of HSPCs (26).  
 
2-2. The role of adhesion molecules in 
tethering and retaining HSPCs in their niches. A 
number of adhesion molecules like P-selectin, E-
selectin, integrin/ receptor pairs, immunoglobulins and 
other adhesion receptors mediate the anchoring  of 
HSPCs within the BM (19). Novel non-integrin 
adhesion receptors have also been identified. For 
instance, HSPCs were shown to express a glycoform 
of CD44 known as hematopoietic cell E-/L-selectin 
ligand, a very potent adhesion molecule that allows 
blood-borne cells to broke, contact and roll along the 
endothelium (27). New researches approved the 
participation of the CD34 Ag in adhesion and/or the 
likely homing of lympho- hematopoietic progenitors. 
This has been attributed to the presence of a large 
number of carbohydrate moieties attached within the 
extracellular region that provide antigenicity and  
attaining the mucin-like structure of an adhesion 
molecule (28). Moreover it was reported that adhesion 
receptor of Sialomucin core protein 24(CD164), with 
associating to CXCR4 provide condition to interact 
CXCR4 with integrins VLA-4 and VLA-5 (29) . 
CD164 itself regulates the adhesion of CD34+ cells to 
BM stroma and their recruitment into the cycle. In 
another study, inhibition of the integrinα4 receptor 
virtually abrogated the homing of HPC to the BM 
(30). On the other hand, blockade of α6 integrin 
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enhanced the homing of human BM-derived HSPC 
and led to significantly improved engraftment (31). 
Aside from the established role of the α_4 β_1 
integrin receptor VCAM-1in the homing of HSPCs 
to the BM, the importance of  MAdCAM-1 and its 
ligand,α_4 β_7 integrin, in the homing of BM-
derived HSPCs to both the spleen and the BM has 
been recently postulated (32). Additionally, Annexin 
II, expressed at high levels by osteoblasts and 
endothelial cells was shown to mediate adhesive 
interactions, between HSPCs and osteoblasts mainly 
through its N-terminal (33). Hyaluronan-mediated 
adhesion of  HSPCs to stabilin-2-transfected cells 
suggests that stabilin-2 also contributes to the 
adhesion and homing of circulating stem and 
progenitor cells to BM (34). N-Cadherin-mediated 
cell adhesion was shown to be required for the 
establishment of hematopoiesis in the BM niche after 
transplantation (35).  
 
2-3.The role of SDF-1/CXCR4 axis in 
migration of HSPC to their niche. SDF-1 is also 
known as CXCL-12 or pre B cell growth stimulating 
factor was primary known as a colony growth 
stimulating factor. SDF-1 is produce by osteoblast 
cells in endosteum region and increase by HIF-1 in 
the BM microenvironment, SDF-1α is produced 
mainly by endothelial cells, fibroblastic cells and 
osteoblasts. It provides a potent retention signal for 
HSPCs mediated via its receptor CXCR4 expressed 
on these cells. The CXCR4 as mentioned previously 
is a kind of hepta-helical-receptors which is coupled 
to GTP-binding proteins and also act as HIV-1 virus 
receptor. SDF-1 mediates HSPC adhesion through 
activation of lymphocyte function- associated 
antigen-1(LFA-1), very late antigen-4 and 5. (VLA-
4&5). The role of SDF-1/CXCR4 axis in the homing 
of HSPC has been demonstrated in non-obese 
diabetic/severe combined immunodeficiency 
(NOD/SCID) mice (22). It has been suggested that 
for optimal signaling, CXCR4 must be incorporated 
into membrane lipid rafts (36, 37). Molecules such as 
fibronectin, fibrinogen fragments, soluble VCAM-1, 
platelet-derived micro particles 
(PMPs),C_3aanaphylatoxin and hyaluronic acid(HA) 
which are present in the supernatants from 
leukapheresis products of patients mobilized with G-
CSF, increase the chemotactic responsiveness of 
HSPCs to an SDF-1 gradient (38). These molecules do 
not chemo attract HSPCs but they prime the 
chemotactic response of HSPCs to a low or threshold 
dose of SDF-1 and this chemotaxis is dependent on the 
cell membrane cholesterol content and the 
incorporation of CXCR4 into membrane lipid rafts 
(38). In order to access a favorable clinical outcome of 
HSPCs, the number of HSPCs should be 
approximately 2-3×106 /_Kgr. Gene expression can be 
regulated by chromatin remodeling and histone 
deacetylase (HDAC) that participates in the regulation 
of chromatin structure (39). Valporicacid (VPA) is a 
specific and potent short-chain HDAC inhibitor that 
has been shown to stimulate proliferation and self-
renewal of normal HSPCs(40). It is known that HSPCs 
derived from PB have superior homing and 
engraftment capabilities compared to those derived 
from BM(41). Evidence suggest that the improved 
engraftment of mobilized HSPCs could be attributed 
to components such as PMPs which are found in the 
elevated levels in the supernatant of leukapheresis 
products to which HSPC have been exposed(41). 
Micro particles were  previously regarded as mere 
cellular debris but they have recently been recognized 
to play a role in many cellular functions(41). PMPs are 
released upon activation of platelets and express 
several functional membrane receptors, including 
CXCR4. Investigations suggest that pre-treatment of 
CD34+ cells with PMPs may prove to be a strategy for 
accelerating engraftment of BM or CB HSPCs (41). 
CD41 is efficiently transferred by PMPs to 
hematopoietic precursors, resulting in their increased 
adhesion to fibrinogen(42). PMPs were also shown to 
enhance in vitro invasive potential of breast cancer 
cells lines and induce metastasis in lung cancer by up 
regulating the expression of the proteolytic enzymes 
such as MMP-2, MMP-9 and MT1_MMP. Other 
molecules present in leukapheresis products that could 
contribute to priming of the chemotactic responses of 
HSPCs towards SDF-1 are HA and thrombin. 
Thrombin, through proteolytic activation of its 
receptor PAR-1, elicits numerous cellular responses in 
platelets and endothelial cells, such as induction of 
adhesion molecules, production of chemokines, 
activation of pro MMP-2, cytoskeletal reorganization 
and cell migration(43). 
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2-4.The role of proteases in HSPCs homing. 
New evidences suggest that Hemagglutinin (HA) and 
thrombin prime homing-related responses of HSPC 
towards SDF-1 by up regulating MT1-MMP 
expression, which in turn leads to pro MMP-2 
activation(44). Activated  MMP-2  have a negative 
feedback in cascade of activation of other 
MMPs(45). It has been demonstrated that 
intracellular crosstalk and positive feedback loops 
between phosphatidylinositol3-kinase(PI3K)-
AKT(46) and the Rho family GTPases including 
Rac, Rho and Cdc42 regulate actin cytoskeletal 
dynamics and F-actin polymerization(47-50). 
Moreover, Rac-1 GTPse signaling pathways lead to 
localized signal amplification which in turn results in 
enhanced F-actin polymerization and 
chemotaxis(51). In CD34+ cells, both PI3K and Rac-
1 GTPase pathways are activated by HA and 
thrombin(52). Intracellular crosstalk occurs between 
these signaling pathways since inhibition of PI3K , 
and Rac-1GTPase attenuate Rac-1 activation, and 
phosphorylation of AKT, respectively. Moreover,  
during HSPC homing SDF-1/CXCR4 signaling 
occurs in the lipid rafts where CXCR4 and Rac-1 
assemble together, thus allowing an optimal 
chemotactic response to SDF_1(52). Hence HA and 
thrombin corporate with the SDF-1/CXCR4 axis by 
signal amplification -activating PI3K and Rac-1 in 
the presence of a weak SDF-1.. This signal functions 
are proteolysis. Overall, these signals could enhance 
homing-related responses of HSPCs and potentially 
speed upengraftment.  
 
3. HSPCs Mobilization 
Stem cell mobilization- release of HSPCs in to 
the peripheral blood of patient in responds to 
chemotherapy or cytokine stimulation was first 
described in the late 1970s and early 1980(7). HSPCs 
transplantation, a clinical procedure has been 
successfully performed for decades to treat various 
cancers and diseases of the blood and immune 
system(1), in which cells with ability to 
reconstituting normal BM function are administered 
to a patient, Traditionally, in both autologous and 
allogenic transplantation, HSPCs were collected by 
multiple aspiration of BM, but such harvesting 
procedure has now been almost completely replaced 
with the collection of PB. Circulated HPSCs have 
been extensively applied clinical conditions such as 
restoration of hematopoiesis following radiotherapy 
and chemotherapy for cancer patients. Many reviews 
on the biology of HSPCs mobilization (53-61)and 
strategies to improve HSPC collection have been 
published recently(8, 58, 62, 63). Table 2 
 
3-2.The role of cytokines and growth factors 
in mobilization. Under steady state conditions, a 
small percentage of HSPCs (0.01-0.05%) are in the 
circulation; however, this number is significantly 
increased upon administration of hematopoietic 
growth factors(64, 65).  
Granulocyte colony stimulating factor( G-CSF, 
filgrastim) and GM-CSF(sargramostim) are currently 
the only cytokines approved by the FDA for HSPC 
mobilization, with G-CSF being the standard of care 
for initial mobilization therapy(66). G-CSF- mobilized 
HPSCs engraft better and have fewer adverse reactions 
compared to those from BM or umbilical cord 
blood(CB). G-CSF is a short-lived protein, with a half-
life of 3.5 h in humans. Multiple injections are 
therefore required to achieve the desired therapeutic 
outcomes in both neutropenia and stem cell 
mobilization.In fact, G-CSF is the most important 
mobilizer substance but has not been administered 
very much due to toxigenic, adverse effects, multiple 
injections and different individual responds(4, 52, 67, 
68). G-CSF induces activation of proteases, inhibition 
of adhesion molecules and attenuation of 
CXCR4/CXCL12signalling. G-CSF downregulates the 
expression of CXCR4 on cells surface so it causes 
mobilization of HSPCs to the PB.  
Following G-CSF administration, the marrow 
microenvironment would be rich in proteolytic 
enzymes released by neutrophils, including 
metalloproteinase-9 (MMP-9), neutrophil elastase, and 
Cathepsin G (69). MMP-9, neutrophil elastase, and 
Cathepsin G can cleave and functionally inactivate 
SDF-1(8, 24, 70). Further, a study in MMP-9–
deficient mice detected defective G-CSF–induced 
mobilization of hematopoietic progenitor cells (71). 
G-CSF down-regulates the expression of 
CXCR4 on BM myeloid cell lines but not on 
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lymphocytes. One problem with the clinical use of 
G-CSF as a mobilizing agent is that its 
unglycosilated recombinant form is rapidly decay 
and been cleared into the plasma, so needs to be 
injected daily. To overcome this the polyethylene 
glycol(PEG) moiety is bound with G-CSF, a masking 
proteolytic cleavage sites and elevation in the level of 
G-CSF would be seen which are sustained for up to 
14 days after a single injection (72).it has also been 
shown that G-CSF  binds non- covalently but with 
high affinity and specificity to polyethylene glycated 
liposomes, which extends its circulation time and 
results in higher G-CSF levels several hours after 
both subcutaneous and intravenous injections 
(73).Alternative regimens have been suggested based 
on pre-clinical finding for example the cytokine 
GROβ mobilizes more murine  
Scal+-c-kit+-lin-HSPC when used alone and 
synergizes with G-CSF(74). GROβ mobilizes HSPCs 
within 15 minutes, suggesting that a readily 
accessible large pool of HSPCs likely associated with 
sinusoidal endothelium can be readily mobilized. 
Combining G-CSF with other growth factors has also 
been attempted (58). For example recombinant 
human stem cell factor (SCF ancetim) shows 
promising synergy when used in combination with 
G-CSF. Moreover, such synergy provides an 
alternative option for patients who mobilize poorly 
or/ and exhibit refractory BM failure(75, 76). In 
another study co-administration of IL-8 and Flt3- 
ligand led to a synergistic enhancement of HSPC 
mobilization on days 3 and 5, compared to either 
used alone(77). Also there are elevated levels of 
hepatocyte growth factor (HGF) in the plasma of 
patients mobilizes with G-CSF. The HGF level 
positively correlated with the number of  CD34+cells 
and WBCs in the PB, being low in patients who were 
poor mobilizer (78). There are two kinds of CD34+ 
stem cells: 
Umbilical CD34+ and mobilized CD34+.  
The HGF receptor C-met is highly express on 
circulated CD34+ cells but not express on steady 
state BM CD34+ cells. It has been suggested that 
during G-CSF induced mobilization, C-met 
expression would increase on BM HSPCs and 
myeloid cells which renders them more responsive to 
the HGF gradient in the circulating PB(79). 
Moreover, G-CSF, together with HGF, increased the 
secretion of  MMP 9 and membrane type1- 
MMP(MT1-MMP) on the surface of BM 
leukocytes(17, 79).  
 
3-3.The role of SDF-1/CXCR4 axis in HSPCs 
mobilization. SDF-1, pre B cell growth- stimulating 
factor,(PBSF) is a kind of CXC chemokines which 
previously was known as B cell colony stimulating 
factor. Its receptor is CXCR4 which is a heptad chain 
helix receptor, binds to GTP binding proteins. CXCR4 
acts as a receptor for HIV-1. SDF-1 is the main 
chemokine involved in HSPC migration(78); in fact, 
most of the cytokines and growth factors mediate 
HSPC mobilization via modulation of SDF-1 or its 
receptor CXCR4(80). It has been demonstrated that 
neutralizing SDF1/CXCR4 antibodies significantly 
reduce HSPC mobilization(81). Following G-CSF 
administration, SDF-1 levels transiently increase in the 
BM, followed by down regulation at the gene (82) and 
protein level(83). Moreover, G-CSF downregulates 
CXCR4 expression in human BM myeloid cells which 
attenuates their response to an SDF-1 gradient (84). 
Thus disruption of SDF-1/CXCR4 signaling is a key 
step in the release of HSPC from the BM to the PB 
during mobilization. Human SDF-1 is composed of 
three distinct structural regions: an N terminus, a 
central core region of three anti parallel β-sheets and a 
C-terminal helix. Previous studies have demonstrated 
the essential role of the N-terminus, particularly the 
first nine residues, as the major site for direct 
interaction with the CXCR4 receptor and subsequent 
signal transduction (85). Modulation of this interaction 
has been harnessed for application in mobilization. 
AAMD3100 or Plerixafor is an effective alternative 
for the collection of sufficient numbers of  CD34+ 
cells for autologous transplantation in patients with 
poor mobilization. A continuous infusion of saturating 
dose of AMD3100 is also  found to be an efficacious 
mobilization regime (25). The cleavage of SDF-1 at 
the N-terminus is effected by various enzymes such as 
MMPs(72) CD26/dipeptidylepeptidaz 4(86), the serine 
proteases Cathepsin G(87) and elastase (42). Such 
enzymes generate distinct truncated forms of SDF-1 
that are functionally inactivate. In addition, the major 
bone-responding proteinase, Cathepsin K elevates 
SDF-1(88). These enzymes are thought to be released 
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particularly by neutrophils during G-CSF injection in 
the BM microenvironment(89). The C-terminus of 
SDF-1 may also have a functional role while its 
cleavage by serum carboxyl peptidase N(CPN) that 
rescue the ability of SDF-1 to bind to heparin and to 
stimulate chemotaxis(89, 90).  
The membrane- bound carboxypeptidase M 
(CPM), which is ideally situated to elicit a more 
targets activity at local tissue sites than soluble CPN, 
is also able to cleave the C- terminal of SDF-1. CPM  
cleaves the C-terminal lysine residue of the α isoform 
of SDF-1 resulting in a decrease of its 
chemoattractant activity towards CD34+HSPCs and 
find that G-CSF strongly upregulates CPM 
expression at the gene and protein levels in 
(mononuclear cells) MNCs and PMNs(44). As it has 
been suggested that the C-terminal  lysine of SDF-1α 
contributes to the tethering of SDF-1 to heparin on 
the cell surface and preserving its activity(91). 
Hence, it seems that cleaving of lysine by CPM 
facilitates the release of SDF-1 from the cell surface, 
and exposes it to further degradation by other 
proteases(44). Degrading the CXCR4 receptor is 
another way by which chemoattraction can be 
abrogated. Leukocyte elastase is able to cleave the N-
terminal of CXCR4(42) that disrupts binging with its 
ligand SDF-1. HIF-1 concentration is elevated in 
some particular organs like brain, heart and liver 
leading to increasing in SDF-1 expression (Fig 1). 
 
3-4.The role of matrix metalloproteinases 
(MMP) in HSPC mobilization. Matrix 
metalloproteinases (MMPs) form a family of closely 
related, zinc-dependent end proteinases. The first 
report about MMPs dates back to 1962, when Gross 
and Lapiere, while attempting to establish how a 
tadpole loses its tail during metamorphosis, 
discovered the first member of this family(MMP-1). 
Since then, the family has expanded gradually with  a 
total of23 human MMPs; the latest member 
discovered is MMP-28 (92). As their name suggests, 
MMPs were characterized initially as matrix-
degrading proteases. Indeed, these enzymes can 
degrade all components of the extracellular matrix 
(ECM), which involve in  many important processes, 
such as cell proliferation, differentiation, migration, 
and death, as well as cell– cell interactions(3). It is 
therefore not surprising that MMPs can play a crucial 
role in many physiological processes, e.g., bone 
morphogenesis, the menstrual cycle, development and 
also, in many pathological conditions including cancer 
invasion, arthritis, and atherosclerosis. The story has 
been made even more complex by their creasing 
number of studies revealing many non-matrix 
substrates for MMPs, such as chemokines, growth 
factors, and receptors, indicating that MMPs influence 
an even wider array of physiological and pathological 
processes4. Inflammatory conditions are almost 
always characterized by increased MMP activities 
(93). G-CSF-activated neutrophils release proteolytic 
enzymes degrading various components of the BM 
microenvironment that are implicated in HSPCs 
mobilization. One of the enzymes that is abundantly 
secreted by neutrophils is MMP 9, which substrates 
extend from the conventional ECM components(eg; 
collagens, fibronectin, laminin, proteoglycans) to non-
mature molecules(46-48). MMPs have been 
traditionally considered to facilitate cell migration 
with breaching basement membrane barriers 
comprised of matrix proteins. Furthermore, , the 
gelatinizes MMP2 and/ or MMP 9 are expressed by 
normal  mobilized CD34+ HSPC as well as stromal 
cells, fibroblasts, endothelial cells and long- term 
marrow culture cells  .( 50 ,51) However, the steady 
state BM CD34+ cells, unlike circulating PB CD34+ 
cells, have no the expression of MMP 2 and MMP 9. 
Moreover, various cytokines and growth factors, 
including IL-3,IL-6,G-CSF,M-CSF, SCF and TNFα 
which are endogenously produced in the BM 
microenvironment (94), could induce the secretion of  
MMP 2 and  MMP 9 by BM CD34+ cells and up 
regulate their trans- migration across reconstituted 
basement membrane by 50% to 150%. Further, the 
trans- matrigel migration of  CD34+ cells is  reduce by 
antibodies against the MMP 2,MMP 9 tissue inhibitors 
of metalloproteinases (TIMP-1and TIPMP-2) and the 
synthetic protease inhibitor, o-phenantrolin (25). 
Furthermore, the cytokines IL-8 and MIP-1  also 
directly stimulate the secretion of bothMMP 2  MMP 
9 in BM CD34+ cells (94). MT1-MMP degrades ECM 
macromolecules, cytokines, chemokines and adhesion 
molecules and mediates tumor cell migration. For 
example, MT1-MMP cleaves CD34+ marker and 
SDF-1 that is resulted in detachment and reduced 
Homing and mobilization of hematopoietic stem cells                                                                                               Rahimi et al. 
Vol 2, No 4,  Fall  2016 
147 
egression of HSPC from the BM (95, 96). Previous 
investigations suggested that MY1-MMP facilitates 
the migration of MSC, CB CD34+  cells and exvivo-
expanded megakaryocytic progenitors(96, 97). 
Recent studies approved the role of MT1-MMP in 
the mobilization of HSPCs from BM(98). CD26 is a 
membrane-bound extracellular peptidase that cleaves 
dipeptides from the N-terminus of polypeptide chains 
after a proline or an alanine(99). The N-terminus of 
chemokines is known to interact with the 
extracellular portion of chemokine receptors (100). 
CD26 affect CXCL12 and CCL22 which are 
expressed on CB CD34+; hence CD26  is play a 
crucial role in G-CSF-mobilized HSPCs. In addition 
to CD26 , which is also expressed by HSPC, has 
been shown to cleave and inactivate SDF-1 and 
consequently, mobilization is reduced with CD26 
inhibition or CD26 deficient mice(101). Other 
proteases implicated in HSPCs mobilization include 
plasminogen activator inhibitor-1 (Pai-1), α2-
antiplasmin. Inhibitor Pai-1 and α2-antiplasmin 
increases HSPCs mobilization in response to G-
CSF(101, 102). Moreover, thrombolytic agents 
enhance HPC mobilization in mice and humans, 
indicating a possible role for plasmin in augmenting 
G-CSF-induced HPSC mobilization. Recently, the 
expression, secretion and function of the cysteine 
protease Cathepsin X by cells of the human BM has 
been examined with interesting results. Osteoblasts 
and stromal cells but not HSPCs secrete Cathepsin X. 
Activated Cathepsin X enhances mobilization with 
reducing cellular adhesive interaction between CD34+ 
HSPC and osteoblast, and digesting SDF-1/ 
CXL12(103). Moreover, recent data suggest that the 
destruction of VCAM1/VLA4 axis with a small 
molecule inhibition of VLA4, BIOS192, results in a 
30-fold increase in mobilization of HSPCs, over basal 
level. Further, 3-fold increase in HSPCs mobilization 
has been reported when AMD3100, a small molecule 
inhibitor of theCXCR4/SDF-1 axis, is combine with 
BIOS192. Furthermore, the combination of G-CSF, 
BIOS192, and AMD3100 enhance mobilization by 17- 
fold compare G-CSF alone.  
 
3-5.The role of ROS in HSPCs mobilization. 
The PBSCs leave their original hypoxic living 
environment their intracellular reactive oxygen 
species(ROS) level changes. Some studies also show 
that the ROS level are increased during in vivo 
mobilization and in vitro culture, causing the 
biological functions to change as well(1, 2). ROS are 
products of cells utilizing oxygen for energy 
metabolism. The antioxidants of the cells can remove 
the continually produced ROS and maintain the ROS 
 
Figure 1. Homing and mobilization HSPC : CXCR4 bind to SDF-1 secreted by osteoblast cells and lead to homing HSPC. 
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at a low level, thereby regulating the proliferation, 
growth, signal transduction and gene expression of 
the cells. When the ROS production in the cells 
increases or antioxidant capacity of the cells 
weakens, ROS stress occurs. The ROS stress changes 
the properties and functions of HSPCs, and is caused 
to cell mitochondrial DNA damage and apoptosis (4). 
The production of ROS is dependent  on oxygen 
concentration and directly affects the capacity of 
HSPCs for self-renewal(5). In the view of negative 
effects of ROS on PBSCs, Haao and et.al, considered 
the effect of two antioxidants, including GSH and 
ascorbic Acid 2-phosphat (AA2P) derivate of vit-c in 
the mobilization process and in vitro amplification of 
BM HSPCs to eliminate the effects of ROS on 
HSPCs. The application ofAA2P may become 
effective methods for protecting the HSPCs 
reconstitution capacity of PBSCs, and improving the 
success rate of PBSCT.  
 
3-6.The role of adhesion molecules and 
other factors in HSPCs mobilization. Integrins are 
a major family of adhesion molecules that mediate 
cell-to-cell and cell-to-matrix interactions. The 
binding of HSPCs through VLA4with VCAM-1 on 
BM stromal cells was found to be essential for the 
homeostatic distribution of HSPCs (104)  and 
recently were approved that the alpha cytoplasmic 
domain plays a critical role(105). The monoclonal 
anti-VLA-4 antibody (natulizumAb) has been shown 
in the clinic to mobilize CD34+ HSPC(106). CD44 is 
the cell-surface glycoprotein receptor for HA and can 
also interact with other ligands such as osteopontin, 
collagens and MMPs (107). HPSCs bind to various 
ECM components and blocking  CD44  is resulted in 
mobilization of murine HSPC(12). In clinical trials, a 
significant decrease in CD44 expression was 
observed during G-CSF- induced mobilization(13). 
Other factors have also been implicated in HSPC 
mobilization, including hormones and 
neurotransmitters (108). As mentioned previously, 
HSPCs are localized in close proximity to 
osteoblastic cells, lining on the endosteal surface of 
the bone. Osteoblasts are known to respond to 
parathyroid hormone(PTH), the endocrine regulator 
of calcium concentration in extracellular fluid(6). 
Injecting mice with PTH lead to a significant 
increase in the SC enriched subpopulation (lin- sca+ 
C-kit+) in the BM(109). In addition stimulated 
granulocytes and monocytes via C5a fragment of 
complement system induce reduction in CXCR4 
expression and also chemotaxis towards an SDF-1 
gradient which leads to increased secretion of MMP-9 
and expression of MT1-MMP and carboxypeptidase 
M. These findings showed that C5a fragment of 
complement   system as a part of innate immune 
system play an important role in subsequent 
mobilization of hematopoietic stem cells towards 
peripheral blood (110). 
 
Conclusion 
The factors such as SDF-1/CXCR4  and other 
adhesion molecules have the important role in homing 
HSPCs. Although the essential ligand for SDF-1 is the 
CXCR4,but it can also attach to CXCR7,thus the 
CXCR7-expressing cells also can be also homing to 
HPSC  but this is yet unclear. Other adhesion 
molecules such as LFA1, CD44 and VLA4 can also 
contribute to homing HSPCs .These adhesion 
molecules expressed on the HSPCS can bind to their 
receptors on the osteoblast cells. So any change in the 
stability of these connections can cause mobilization 
HSPCs and their egression from BM  into the 
circulation.  Many other  factors can have role in the 
mobilization including  G-CSF(the key factor), 
GM.CSF,MMPs especially MMP2 and MMP9 and 
adhesion molecules. G-CSF is one of the most 
common factors that by use number of  the 
mechanisms  can contribute to HSPCs mobilization 
such as degranulation of neutrophil granular contents 
that result in to increase in metalloproteases which 
break connections between SDF-1/CXCR4 and other 
adhesion molecules, finally migration  HSPCs into the  
circulation . Metalloproteinase such MMP2, 9 also can 
break the connection  HSPCs to osteoblast cells in the 
bone marrow. According to above, we can rich the 
peripheral blood of HSPCS by using of this factors 
and antagonist for this receptors on the osteoblastic 
cells or/and HSPCS for bone marrow transplant. 
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